Drugs / TRK-250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03727802 | Nov 2018 → Apr 2022 | idiopathic pulmonary fibrosis | Toray Industries, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRK-250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03727802 ↗ |
| Action | Inhibit | “TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1)...” NCT03727802 ↗ |
| Modality | Small interfering RNA (siRNA) | “A Phase I Study of TRK-250, a Novel siRNA-Based Oligonucleotide, in Patients” PMID 37738329 ↗ Sep 2023 |